Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Return on Sales (2017 - 2023)

Acro Biomedical (ACBM) has 7 years of Return on Sales data on record, last reported at 35.34% in Q3 2023.

  • For Q3 2023, Return on Sales fell 2451.0% year-over-year to 35.34%; the TTM value through Sep 2023 reached 35.34%, down 2451.0%, while the annual FY2022 figure was 24.1%, 2275.0% down from the prior year.
  • Return on Sales reached 35.34% in Q3 2023 per ACBM's latest filing, up from 42.07% in the prior quarter.
  • Across five years, Return on Sales topped out at 7.88% in Q3 2019 and bottomed at 44.3% in Q1 2023.
  • Average Return on Sales over 5 years is 8.58%, with a median of 0.6% recorded in 2021.
  • Peak YoY movement for Return on Sales: soared 781bps in 2019, then crashed -3238bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.07% in 2019, then tumbled by -361bps to 0.17% in 2020, then soared by 2279bps to 3.72% in 2021, then tumbled by -394bps to 10.93% in 2022, then tumbled by -223bps to 35.34% in 2023.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 35.34% in Q3 2023, 42.07% in Q2 2023, and 44.3% in Q1 2023.